- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
Patent holdings for IPC class C07D 271/06
Total number of patents in this class: 968
10-year publication summary
|
99
|
111
|
104
|
100
|
74
|
60
|
64
|
59
|
37
|
18
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 21165 |
61 |
| Syngenta Participations AG | 1568 |
36 |
| Receptos LLC | 61 |
26 |
| Bristol-myers Squibb Company | 4789 |
25 |
| PTC Therapeutics, Inc. | 476 |
25 |
| Aurigene Oncology Limited | 128 |
21 |
| PI Industries Ltd | 189 |
18 |
| Syngenta Crop Protection AG | 6577 |
17 |
| King Faisal University | 930 |
17 |
| The Scripps Research Institute | 1343 |
16 |
| Cytokinetics, Inc. | 256 |
14 |
| Abbvie Inc. | 1837 |
12 |
| Merck Sharp & Dohme LLC | 3737 |
12 |
| Sumitomo Chemical Company, Limited | 9015 |
11 |
| Modernatx, Inc. | 1282 |
10 |
| Theravance Biopharma R&D IP, LLC | 416 |
10 |
| Bayer Cropscience AG | 1878 |
9 |
| University of Notre Dame du Lac | 600 |
9 |
| Calico Life Sciences LLC | 106 |
9 |
| Allergan, Inc. | 2198 |
8 |
| Other owners | 602 |